Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
124I-evuzamitide PET/CT in Transthyretin Cardiac Amyloidosis
NCT05635045Phase 2Completed
- Sponsor
- Columbia University
- Start
- Jul 2022
- Primary completion
- May 2024
- Modality
- Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of 124I-evuzamitide in transthyretin amyloidosis (ATTR), sponsored by Columbia University. Started Jul 2022; status: completed.
02
Drugs
124I-evuzamitide
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT05635045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05635045.